Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

• 2022

  Log in to bookmark this resource.

  Log in
• Laura Hammitt; Ron Dagan; Yuan Yuan; Manuel Cots; Miroslava Bosheva; Shabir Madhi
PMID: 35235726DOI: https://doi.org/10.1056/nejmoa2110275

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This study examines the use of nirsevimab, a monoclonal antibody, to prevent respiratory syncytial virus (RSV) infections in healthy late-preterm and term infants. It describes how 1,490 infants were given either nirsevimab or a placebo before RSV season. Results showed that nirsevimab reduced medically attended RSV infections by 74.5% compared to the placebo group. Hospitalizations due to RSV were also lower with nirsevimab but not significantly so. The study found no major safety concerns with using nirsevimab and suggests it could be an effective way to protect young infants from severe respiratory illnesses caused by RSV during their first season of exposure.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antiviral Agents; Drug Administration Schedule; Infant, Newborn; Infant, Premature, Diseases; Injections, Intramuscular; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Premature Birth; Antibodies, Monoclonal, Humanized

Institutions: Johns Hopkins University; AstraZeneca; Ben-Gurion University of the Negev; Quirónsalud Málaga Hospital

---

More like this

Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season 2024 · Ben-Gurion University of the Negev, Johns Hopkins University, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, University of the Witwatersrand Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants 2023 · Northwestern University, University of the Witwatersrand, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, Ben-Gurion University of the Negev Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis from a Phase 3 Randomized Clinical Trial (MELODY) 2024 · AstraZeneca, Ben-Gurion University of the Negev

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---